Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
Sweden
/
Pharmaceuticals & Biotech
/
Oncopeptides
ONCO
Oncopeptides
European Pricing And Regulatory Pressures Will Erode Value
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 2 Analysts
Published
18 Aug 25
Updated
18 Aug 25
0
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
SEK 1.70
213.5% overvalued
intrinsic discount
18 Aug
SEK 5.33
Loading
1Y
142.8%
7D
18.4%
Author's Valuation
SEK 1.7
213.5% overvalued
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
SEK 1.7
213.5% overvalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-2b
408m
2014
2017
2020
2023
2025
2026
2028
Revenue SEK 407.9m
Earnings SEK 87.0m
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
59.59%
Biotech revenue growth rate
12.78%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
4.92%
Calculation
SEK 87.00m
Earnings '28
x
5.87x
PE Ratio '28
=
SEK 510.47m
Market Cap '28
SEK 510.47m
Market Cap '28
/
260.70m
No. shares '28
=
SEK 1.96
Share Price '28
SEK 1.96
Share Price '28
Discounted to 2025 @ 4.92% p.a.
=
SEK 1.70
Fair Value '25
